← Leaderboards
Tom Eugene Howard
Sepulveda Research Corporation
$3,706,802
Attributed
$7,866,674
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2009–25$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,866,674 · 2
By mechanism
RC2$6,507,463 · 1
R01$1,359,211 · 1
Top collaborators
- Miguel Escobar2 shared
- Kathleen Palmer Pratt2 shared
- Sarah A. Williams-Blangero2 shared
Others in their field
Top investigators on “Infusion Procedures”
- Myron S Cohen · Family Health International$91,263,426
- Wafaa M. El-Sadr · Columbia University Health Sciences$91,263,426
- Georgia D Tomaras · Fred Hutchinson Cancer Center$70,233,271
- Dan H. Barouch · Fred Hutchinson Cancer Center$63,804,365
- Lawrence Corey · Fred Hutchinson Cancer Center$58,962,452
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$58,962,452
Research focus
Infusion ProceduresRepositoryFutureIncidencePlasmaRaceCollaborationsFactor ViiiHemorrhageImmunogenicityMutationPeptidesAntibodiesProteinsBlood CoagulationAllelesBlood SpecimenEnrollmentGeneticHemophilia AImmune ResponseImmunogenicLifeResources
Grant awards (4)
Omic Approaches to Factor VIII Inhibitor Development in Hemophilia Patients of Mexican Descent$673,590
R01 · FY2025 · HL · contact PI
Omic Approaches to Factor VIII Inhibitor Development in Hemophilia Patients of Mexican Descent$685,621
R01 · FY2024 · HL · contact PI
Mechanisms of Race-Based Differences in Factor VIII Immunogenicity in Hemophilia$2,958,699
RC2 · FY2010 · HL · contact PI
Mechanisms of Race-Based Differences in Factor VIII Immunogenicity in Hemophilia$3,548,764
RC2 · FY2009 · HL · contact PI